We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Aureon Laboratories to Collaborate with Pfizer
News

Aureon Laboratories to Collaborate with Pfizer

Aureon Laboratories to Collaborate with Pfizer
News

Aureon Laboratories to Collaborate with Pfizer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Aureon Laboratories to Collaborate with Pfizer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aureon Laboratories, Inc. has announced a new phase in a research collaboration with Pfizer, Inc. that shall establish quantitative biometrics for assessing therapeutic response derived from studies focusing on prostate cancer.

The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome.

The collaboration is an extension of a previous study performed by Aureon and Pfizer to evaluate prostatectomy samples from patients treated with neo-adjuvant androgen deprivation therapy (ADT).

The previous project also demonstrated the technical feasibility of Aureon’s platform in quantifying T-cell subtypes in a lymphoid infiltrate and the cellular distribution of cytokines using intact formalin-fixed, paraffin-embedded (FFPE) tissue specimens.

Vijay Aggarwal, PhD, CEO and President of Aureon Laboratories said, “We are very excited about collaborating with Pfizer on the next phase of this research project. Aureon’s ability to integrate and quantify histological features and cell-type specific molecular biomarkers in intact paraffin-embedded tissue allows a better understanding of the biological context in terms of assessing therapeutic response.”

Advertisement